OSE Immunotherapeutics to Present at 4th Annual Immuno-Oncology: BD&L and Investment Forum Forum to be held in Chicago, IL, on June 1, 2018

Alexis Peyroles, chief executive officer, will provide a Company update, including recent accomplishments and future plans, at the upcoming 4th Annual Immuno-Oncology: BD&L and Investment Forum…

OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi® in Immuno-Oncology Applications

The new patent extends the U.S. protection of Tedopi® to several combinations of  neoepitopes…


COO, Alexis Peyroles, recently interviewed by SCRIP’s Lucie Ellis at EBDgroup’s BIOEurope conference

Access to the interview

March 7, 2017

10th Annual European Life Science CEO Forum & Exhibition, Zürich

To access the presentation


OSE Immunotherapeutics blocks SIRPA to feed and rewire myeloid cells in cancer – The flipside of CD47

OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology

7 November 2016

Catching Up with the French Leader in Immuno-Oncology #BIO Europe, interview of Dominique Costantini by Philip Hemme

21 October 2016

Immuno-Oncology News: Preclinical Data of New Checkpoint Inhibitor Effi-DEM to Be Presented at ICI Conference, Nov. 16-18, by Daniela Semedo

11 October 2016

MedicalResearch.com, interview with Bernard Vanhove, COO, R&D and International scientific collaborations: Novel Immune Checkpoint Inhibitor Has Potential Against Variety of Tumors

July 5, 2016

OSE Immuno valide un accord à 155 millions avec l’américain J&J, Les Echos, by Chantal Houzelle

July 5, 2016

OSE Immunotherapeutics : levée d’option de Janssen sur FR104, Le Revenu, by Laurent Grassin

June 5, 2016

OSE Immunotherapeutics annonce la levée d’option de licence par Janssen Biotech, BMF Intégrale Bourse, interview

Cédric Decœur

July 5. 2016

J&J bags CD28 antagonist from OSE in €155M autoimmune deal, FierceBiotech

June 1, 2016

OSE Immunotherapeutics : “Nous avons 18 mois de visibilité”, Dominique Costantini, DG, TV Finance, Interview by Lucie Morlot

May 26, 2016

Bpifrance inno generation : Immunothérapie contre le cancer : vers une révolution attendue

April 19, 2016

BIO-Europe Spring® 2016 : OSE Pharma, Effimune merging to create European immunotherapy company

March 3, 2016


“Le rapprochement avec Effimune s’appuie sur de vraies synergies”

February 26, 2016


Pourquoi Ose Pharma absorbe Effimune en immunothérapie

February 25, 2016


OSE Pharma to merge with Effimune to build out immunotherapy pipeline

February 25, 2016


OSE Pharma et Effimune projettent de fusionner

February 25, 2016

Biotech-Finances vignette full

« Ose Immunotherapeutics : créer un leader dans l’immunothérapie » Dominique Costantini, OSE Pharma

February 5, 2016


OSE Pharma a lancé une étude de phase 3 sur Tedopi aux États-Unis

January 8, 2016

Biotech-Finances vignette full

« Notre meilleur atout est la phase III », Dominique Costantini, Ose Pharma

January 8, 2016

Biotech-Finances vignette full

Après le démarrage de la phase pivot de Tedopi, OSE Pharma veut faire avancer d’autres projets en 2016



L’actu de bpifrance

17 juin 2013

OSE Pharma reçoit un financement d’Oséo dans le cadre d’un concours national, organisé par BPI France.


Le vaccin d’Ose Pharma veut soigner le cancer du poumon

23 février 2013

Sign up to receive press releases by email.

Subscribe to our newsletter

Select one or more lists: